cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14429105.v1
title: Additional file 5 of Eudiplozoon nipponicum (Monogenea, Diplozoidae) and its adaptation to haematophagy as revealed by transcriptome and secretome profiling

description: Additional file 5: Table S5. Spreadsheet with observed E. nipponicum KEGG Modules (by KAAS analysis) with information about the total number of transcripts in each module and the total of TPM and the ratio between the TPM value and the number of transcripts.
DOI: 10.6084/m9.figshare.14429105
title: Additional file 5 of Eudiplozoon nipponicum (Monogenea, Diplozoidae) and its adaptation to haematophagy as revealed by transcriptome and secretome profiling

description: Additional file 5: Table S5. Spreadsheet with observed E. nipponicum KEGG Modules (by KAAS analysis) with information about the total number of transcripts in each module and the total of TPM and the ratio between the TPM value and the number of transcripts.
DOI: 10.6084/m9.figshare.14429108
title: Additional file 6 of Eudiplozoon nipponicum (Monogenea, Diplozoidae) and its adaptation to haematophagy as revealed by transcriptome and secretome profiling

description: Additional file 6: Table S6. Spreadsheet presenting E. nipponicum KEGG Orthologues and pathways. Pathways are linked with K number and quantified by the sum of TPM values of all included transcripts (also presented) and the ratio between the TPM value and the number of transcripts.
DOI: 10.6084/m9.figshare.14429111.v1
title: Additional file 7 of Eudiplozoon nipponicum (Monogenea, Diplozoidae) and its adaptation to haematophagy as revealed by transcriptome and secretome profiling

description: Additional file 7: Table S7. Spreadsheet with a list of E. nipponicum secreted proteins (ESP) identified by LC-MS/MS analysis. Additional information for each protein is molecular weight, pI value, area, coverage, number of detected peptides (total, unique), quantification (SAF and NSAF), and annotation.
DOI: 10.6084/m9.figshare.14429111
title: Additional file 7 of Eudiplozoon nipponicum (Monogenea, Diplozoidae) and its adaptation to haematophagy as revealed by transcriptome and secretome profiling

description: Additional file 7: Table S7. Spreadsheet with a list of E. nipponicum secreted proteins (ESP) identified by LC-MS/MS analysis. Additional information for each protein is molecular weight, pI value, area, coverage, number of detected peptides (total, unique), quantification (SAF and NSAF), and annotation.
DOI: 10.6084/m9.figshare.14429120
title: Additional file 2 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 2. Datafile on endpoint SBP.
DOI: 10.6084/m9.figshare.14429123
title: Additional file 3 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 3. Datafile on endpoint SBP.
DOI: 10.6084/m9.figshare.14429120.v1
title: Additional file 2 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 2. Datafile on endpoint SBP.
DOI: 10.6084/m9.figshare.14429123.v1
title: Additional file 3 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 3. Datafile on endpoint SBP.
DOI: 10.6084/m9.figshare.14429126
title: Additional file 4 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 4. Datafile on endpoint Tchol.
DOI: 10.6084/m9.figshare.14429126.v1
title: Additional file 4 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 4. Datafile on endpoint Tchol.
DOI: 10.6084/m9.figshare.14429129
title: Additional file 5 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 5. Datafile on endpoint Tchol.
DOI: 10.6084/m9.figshare.14429129.v1
title: Additional file 5 of Long-term effects (&gt; 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis

description: Additional file 5. Datafile on endpoint Tchol.
DOI: 10.6084/m9.figshare.14429137
title: Additional file 2 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 2. Folder (CS_1) containing the results (i.e., the output files from the current toolkit) of the FS-LDA, SFS-LDA, RF and GB models for case study 1.
DOI: 10.6084/m9.figshare.14429137.v1
title: Additional file 2 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 2. Folder (CS_1) containing the results (i.e., the output files from the current toolkit) of the FS-LDA, SFS-LDA, RF and GB models for case study 1.
DOI: 10.6084/m9.figshare.14429143
title: Additional file 3 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 3. Folder (CS_2) containing both the input files and the results (i.e., the output files from the current toolkit) of the SFS-LDA models for Case study-2.
DOI: 10.6084/m9.figshare.14429149.v1
title: Additional file 4 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 4. Folder (CS_3) containing both the input files and the results (i.e., the output files from the current toolkit) obtained from the RF model by applying Method1 for Case study-3.
DOI: 10.6084/m9.figshare.14429143.v1
title: Additional file 3 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 3. Folder (CS_2) containing both the input files and the results (i.e., the output files from the current toolkit) of the SFS-LDA models for Case study-2.
DOI: 10.6084/m9.figshare.14429149
title: Additional file 4 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 4. Folder (CS_3) containing both the input files and the results (i.e., the output files from the current toolkit) obtained from the RF model by applying Method1 for Case study-3.
DOI: 10.6084/m9.figshare.14429152
title: Additional file 5 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 5. Folder (CS_4) containing the input file of SFS-LDA and GB models and the results (i.e., the output files from the current toolkit) obtained from the SFS-LDA for Case study-4.
DOI: 10.6084/m9.figshare.14429152.v1
title: Additional file 5 of QSAR-Co-X: an open source toolkit for multitarget QSAR modelling

description: Additional file 5. Folder (CS_4) containing the input file of SFS-LDA and GB models and the results (i.e., the output files from the current toolkit) obtained from the SFS-LDA for Case study-4.
DOI: 10.6084/m9.figshare.14429177
title: Additional file 1 of The complete genome sequence of Listeria monocytogenes strain S2542 and expression of selected genes under high-pressure processing

description: Additional file 1: Table S1. The list of orthologous genes within strains and primers that were used in ddPCR experiments.
DOI: 10.6084/m9.figshare.14429177.v1
title: Additional file 1 of The complete genome sequence of Listeria monocytogenes strain S2542 and expression of selected genes under high-pressure processing

description: Additional file 1: Table S1. The list of orthologous genes within strains and primers that were used in ddPCR experiments.
DOI: 10.6084/m9.figshare.14429189.v1
title: Additional file 1 of Popularity and performance of bioinformatics software: the case of gene set analysis

description: Additional file 1. GSA Reference DB.
DOI: 10.6084/m9.figshare.14429189
title: Additional file 1 of Popularity and performance of bioinformatics software: the case of gene set analysis

description: Additional file 1. GSA Reference DB.
DOI: 10.6084/m9.figshare.14429213
title: Additional file 3 of Sulfur amino acid restriction, energy metabolism and obesity: a study protocol of an 8-week randomized controlled dietary intervention with whole foods and amino acid supplements

description: Additional file 3. Design file for power calculations.
DOI: 10.6084/m9.figshare.14429213.v1
title: Additional file 3 of Sulfur amino acid restriction, energy metabolism and obesity: a study protocol of an 8-week randomized controlled dietary intervention with whole foods and amino acid supplements

description: Additional file 3. Design file for power calculations.
DOI: 10.6084/m9.figshare.14429276
title: Additional file 1 of N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions

description: Additional file 1: Supplementary Table S1. Primers and their sequences used for qRT-PCR.
DOI: 10.6084/m9.figshare.14429276.v1
title: Additional file 1 of N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions

description: Additional file 1: Supplementary Table S1. Primers and their sequences used for qRT-PCR.
DOI: 10.6084/m9.figshare.14429279.v1
title: Additional file 2 of N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions

description: Additional file 2: Supplementary Table S2. Primary and secondary antibodies used for western blotting and immunofluorescence.
DOI: 10.6084/m9.figshare.14429279
title: Additional file 2 of N-acetyl cysteine induces quiescent-like pancreatic stellate cells from an active state and attenuates cancer-stroma interactions

description: Additional file 2: Supplementary Table S2. Primary and secondary antibodies used for western blotting and immunofluorescence.
DOI: 10.6084/m9.figshare.14429284
title: Additional file 1 of Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples

description: Additional file 1. Prevalence, single-type infection and coinfection of hrHPV and lrHPV genotypes detected in participating couples. Statistically significant data (P ≤ 0.05) are shown in bold. HrHPV includes HPV31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82 genotypes. LrHPV includes HPV6, 11, 40, 42, 43, 44/55. The HPV result for a given sample was obtained when at least two detection methods were concordant. The presence of HPV53, 70, 73, 82 and lrHPV genotypes (HPV6, 11, 40, 42, 43, 44/55) was evaluated using PapilloCheck® HPV-Screening only. The presence of HPV in penile swabs was evaluated using PapilloCheck® HPV-Screening only.
DOI: 10.6084/m9.figshare.14429284.v1
title: Additional file 1 of Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples

description: Additional file 1. Prevalence, single-type infection and coinfection of hrHPV and lrHPV genotypes detected in participating couples. Statistically significant data (P ≤ 0.05) are shown in bold. HrHPV includes HPV31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82 genotypes. LrHPV includes HPV6, 11, 40, 42, 43, 44/55. The HPV result for a given sample was obtained when at least two detection methods were concordant. The presence of HPV53, 70, 73, 82 and lrHPV genotypes (HPV6, 11, 40, 42, 43, 44/55) was evaluated using PapilloCheck® HPV-Screening only. The presence of HPV in penile swabs was evaluated using PapilloCheck® HPV-Screening only.
DOI: 10.6084/m9.figshare.14429287
title: Additional file 2 of Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples

description: Additional file 2. HPV concordance in paired samples taken from male and female partners of participating couples. CS cervical swab, PS penile swab, SS semen sample, NA not applicable. Statistically significant data (P-value &lt; 0.05) are shown in bold. *Concordance in any type of sample from male partner with sample from female partner any-type concordance-both partners are HPV positive same-type concordance-both partners are HPV positive for 1 or more HPV types in common.
DOI: 10.6084/m9.figshare.14429287.v1
title: Additional file 2 of Prevalence and genotype distribution of human papillomavirus in Czech non-vaccinated heterosexual couples

description: Additional file 2. HPV concordance in paired samples taken from male and female partners of participating couples. CS cervical swab, PS penile swab, SS semen sample, NA not applicable. Statistically significant data (P-value &lt; 0.05) are shown in bold. *Concordance in any type of sample from male partner with sample from female partner any-type concordance-both partners are HPV positive same-type concordance-both partners are HPV positive for 1 or more HPV types in common.
DOI: 10.6084/m9.figshare.14429395
title: Additional file 1 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 1: Drug-variant associations of the PGx–CNS panel. The PGx–CNS panel includes 28 CNS drugs and to 24 single nucleotide polymorphisms (SNPs). The table summarizes the SNPs and the genes associated to each of the 28 drugs. The corresponding probe IDs and the Evidence Levels (EL) are mentioned. The Level of evidence (EL) of each PGx variant-drug association, adequate for clinical use, in line with PharmGKB. The PGx-CNS panel includes pharmacogenetics associations of clinical significance. Each association has a variable level of evidence (EL), as derived by literature mining, in line with the rating system of "Strength of Evidence” by the PharmGKB [10]. In addition, the associations annotated by the FDA are noted (Actionable: The label may contain information about changes in efficacy, dosage, metabolism or toxicity due to gene/protein/chromosomal variants or phenotypes (e.g. "poor metabolizers"). Or the label may mention contraindication of the drug in a particular subset of patients with particular variants/genotypes/phenotypes. However, the label does not require or recommend gene, protein or chromosomal testing; Informative PGx: The label contains information stating that particular gene/protein/chromosomal variants or metabolizer phenotypes do not affect a drug’s efficacy, dosage, metabolism or toxicity, or its effect is not considered as “clinically” significant, or it does not currently meet the requirements to be assigned as “Actionable PGx”, No recommendation: The PGx association is not mentioned in the FDA's Table of Pharmacogenomic Biomarkers in Drug Labels).
DOI: 10.6084/m9.figshare.14429395.v1
title: Additional file 1 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 1: Drug-variant associations of the PGx–CNS panel. The PGx–CNS panel includes 28 CNS drugs and to 24 single nucleotide polymorphisms (SNPs). The table summarizes the SNPs and the genes associated to each of the 28 drugs. The corresponding probe IDs and the Evidence Levels (EL) are mentioned. The Level of evidence (EL) of each PGx variant-drug association, adequate for clinical use, in line with PharmGKB. The PGx-CNS panel includes pharmacogenetics associations of clinical significance. Each association has a variable level of evidence (EL), as derived by literature mining, in line with the rating system of "Strength of Evidence” by the PharmGKB [10]. In addition, the associations annotated by the FDA are noted (Actionable: The label may contain information about changes in efficacy, dosage, metabolism or toxicity due to gene/protein/chromosomal variants or phenotypes (e.g. "poor metabolizers"). Or the label may mention contraindication of the drug in a particular subset of patients with particular variants/genotypes/phenotypes. However, the label does not require or recommend gene, protein or chromosomal testing; Informative PGx: The label contains information stating that particular gene/protein/chromosomal variants or metabolizer phenotypes do not affect a drug’s efficacy, dosage, metabolism or toxicity, or its effect is not considered as “clinically” significant, or it does not currently meet the requirements to be assigned as “Actionable PGx”, No recommendation: The PGx association is not mentioned in the FDA's Table of Pharmacogenomic Biomarkers in Drug Labels).
DOI: 10.6084/m9.figshare.14429398
title: Additional file 2 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 2: Functional roles of the genes associated with the PGx–CNS panel. The PGx–CNS panel includes 13 genes that were selected for their valuable PGx association with the targeted drugs. The table summarizes the functional roles of their encoded proteins, ranging from metabolization to cell signalling and actionable mechanisms [63–90].
DOI: 10.6084/m9.figshare.14429398.v1
title: Additional file 2 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 2: Functional roles of the genes associated with the PGx–CNS panel. The PGx–CNS panel includes 13 genes that were selected for their valuable PGx association with the targeted drugs. The table summarizes the functional roles of their encoded proteins, ranging from metabolization to cell signalling and actionable mechanisms [63–90].
DOI: 10.6084/m9.figshare.14429401
title: Additional file 3 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 3: Genotypic results (tab1), SNP frequencies (tab2) and comparative population analysis on the occurrences of 24 variants identified on 501 patients (PGx–CNS) and three different populations (CEU, YRI, CHB) (tab3).
DOI: 10.6084/m9.figshare.14429404
title: Additional file 4 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 4: Categorization of identified PGx associations of 28 drugs with 24 SNPs, on 501 patients as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
DOI: 10.6084/m9.figshare.14429404.v1
title: Additional file 4 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 4: Categorization of identified PGx associations of 28 drugs with 24 SNPs, on 501 patients as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
DOI: 10.6084/m9.figshare.14429410
title: Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
DOI: 10.6084/m9.figshare.14429410.v1
title: Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
DOI: 10.6084/m9.figshare.14429401.v1
title: Additional file 3 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 3: Genotypic results (tab1), SNP frequencies (tab2) and comparative population analysis on the occurrences of 24 variants identified on 501 patients (PGx–CNS) and three different populations (CEU, YRI, CHB) (tab3).
DOI: 10.6084/m9.figshare.14429407.v1
title: Additional file 5 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 5: Statistics of the nonlinear principal component analysis (PCA) involving 24 variables (gene variants) and all 501 samples of the PGx–CNS panel.
DOI: 10.6084/m9.figshare.14429407
title: Additional file 5 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)

description: Additional file 5: Statistics of the nonlinear principal component analysis (PCA) involving 24 variables (gene variants) and all 501 samples of the PGx–CNS panel.
DOI: 10.6084/m9.figshare.14429422
title: Additional file 1 of Chronic temperature stress inhibits reproduction and disrupts endocytosis via chaperone titration in Caenorhabditis elegans

description: Additional file 1. DEGs. Worksheet containing the DESeq output file containing statistically differentially expressed genes from each timepoint with read counts, log2 fold-change, and p-values.
DOI: 10.6084/m9.figshare.14429422.v1
title: Additional file 1 of Chronic temperature stress inhibits reproduction and disrupts endocytosis via chaperone titration in Caenorhabditis elegans

description: Additional file 1. DEGs. Worksheet containing the DESeq output file containing statistically differentially expressed genes from each timepoint with read counts, log2 fold-change, and p-values.
DOI: 10.6084/m9.figshare.14429428
title: Additional file 3 of Chronic temperature stress inhibits reproduction and disrupts endocytosis via chaperone titration in Caenorhabditis elegans

description: Additional file 3: Gene lists. Worksheet with separate tabs for: FigS1, all differentially expressed genes shared between Acute (1-h), Mid (24-h), and Chronic (48-h) 28 °C HS; FigS2, all differentially expressed genes shared between Chronic (48-h) 28 °C HS (this work) and Classical Acute HSR genes (33 °C HS for 30 min, from Brunquell et al. [35]); FigS3, GO analysis results including all significantly enriched GO terms and the up- and down-regulated genes from each term for each 28 °C HS timepoint (listed by WormBase ID).